Trends in lipid profiles among South Korean adults: 2005, 2008 and 2010 Korea National Health and Nutrition Examination Survey

Journal of Public Health (United Kingdom)

Volumn 37, Issue 2, 2015, Pages 286-294

  Nam, Ga Eun ^a   Han, Kyungdo ^b   Park, Yong Gyu ^b   Choi, Youn Seon ^a   Kim, Seon Mee ^a   Ju, Sang Yhun ^c   Ko, Byung Joon ^a   Kim, Yang Hyun ^a   Kim, Eun Hye ^a   Cho, Kyung Hwan ^a   Kim, Do Hoon ^a  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

cardiovascular risk; cholesterol; dyslipidemia; lipid; lipoprotein; trends

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; AGED; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NUTRITION; OBESITY; PREVALENCE; SOUTH KOREA;

ADULT; AGED; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PREVALENCE; REPUBLIC OF KOREA;

EID: 84930730070     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdu012     Document Type: Review

References (34)

1. Yan-Ling Z, Dong-Qing Z, Chang-Quan H et al. Cigarette smoking and its association with serum lipid/lipoprotein among Chinese nonagenarians/ centenarians. Lipids Health Dis 2012;11:94.
2. Rana JS, Boekholdt SM, Kastelein JJ et al. The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep 2012;14(2):130-4.
3. Ridker PM, Rifai N, Cook NR et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005;294(3):326-33.
4. Shai I, Rimm EB, Hankinson SE et al. Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004;110(18):2824-30.
5. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract 2008;62(8):1246-54.
6. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251(3):351-64.
7. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251(3):365-74.
8. Grover SA, Abrahamowicz M, Joseph L et al. The benefits of treating hyperlipidemia to prevent coronary heart disease. Estimating changes in life expectancy and morbidity. JAMA 1992;267(6):816-22.
9. Okamura T. Dyslipidemia and cardiovascular disease: A series of epidemiologic studies in Japanese populations. J Epidemiol 2010;20(4): 259-65.
10. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349(9061): 1269-76.
11. Lopez AD. Assessing the burden of mortality from cardiovascular diseases. World Health Stat Q 1993;46(2):91-6.
12. Sekikawa A, Kuller LH, Ueshima H et al. Coronary heart disease mortality trends in men in the post World War II birth cohorts aged 35-44 in Japan, South Korea and Taiwan compared with the United States. Int J Epidemiol 1999;28(6):1044-9.
13. Khang YH, Lynch JW, Kaplan GA. Impact of economic crisis on cause-specific mortality in South Korea. Int J Epidemiol 2005;34(6): 1291-301.
14. Chang HS, Kim HJ, Nam CM et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health 2012; 45(5):291-300.
15. Kang HY, Lim SJ, Suh HS et al. Estimating the lifetime economic burden of stroke according to the age of onset in South Korea: A cost of illness study. BMC Public Health 2011;11:646.
16. Lee MH, Kim HC, Ahn SV et al. Prevalence of dyslipidemia among Korean adults: Korea National Health and Nutrition Survey 1998-2005. Diabetes Metab J 2012;36(1):43-55.
17. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
18. Oh SW, Shin SA, Yun YH et al. Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. Obes Res 2004;12(12):2031-40.
19. Weisell RC. Body mass index as an indicator of obesity. Asia Pac J Clin Nutr 2002;11(Suppl 8):S681-4.
20. Ferrieres J, Bongard V, Dallongeville J et al. Trends in plasma lipids, lipoproteins and dyslipidaemias in French adults, 1996-2007. Arch Cardiovasc Dis 2009;102(4):293-301.
21. Farzadfar F, Finucane MM, Danaei G et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011;377(9765): 578-86.
22. Carroll MD, Kit BK, Lacher DA et al. Trends in lipids and lipoproteins in US adults, 1988-2010. JAMA 2012;308(15):1545-54.
23. Kim SM, Han JH, Park HS. Prevalence of low HDL-cholesterol levels and associated factors among Koreans. Circ J 2006;70(7): 820-6.
24. Song Y, Joung H. A traditional Korean dietary pattern and metabolic syndrome abnormalities. Nutr Metab Cardiovasc Dis 2012;22(5):456-62.
25. Brinton EA, Nanjee MN. Effects of Ethanol Intake on High Density Lipoprotein Metabolism in Humans. High Density Lipoproteins, Dyslipidemia, and Coronary Heart Disease 2010;129-38.
26. Mureddu GF, Brandimarte F, De Luca L. High-density lipoprotein levels and risk of cardiovascular events: A review. J Cardiovasc Med (Hagerstown) 2012;13(9):575-86.
27. Baum SJ, Kris-Etherton PM, Willett WC et al. Fatty acids in cardiovascular health and disease: A comprehensive update. J Clin Lipidol 2012;6(3):216-34.
28. Korea Centers for Disease Control and Prevention. Korea Health Statistics 2010: Korea National Health and Nutrition Examination Survey (KNHANES V-1). http://knhanes.cdc.go.kr/knhanes/index. do (10 July 2013, date last accessed).
29. Wolf G. High-fat, high-cholesterol diet raises plasma HDL cholesterol: studies on the mechanism of this effect. Nutr Rev 1996;54 (1 Pt 1):34-5.
30. Lee K. Cardiovascular risk prevalence, awareness, treatment, and control from 1998 to 2007 in Koreans. Asia Pac J Clin Nutr 2010; 19(2):261-5.
31. Simons LA, Simons J, Friedlander Y et al. Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ 2011;20(4):214-9.
32. Matikainen N, Taskinen MR. Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes. Curr Cardiol Rep 2012;14(6):721-31.
33. Raikou M, McGuire A, Colhoun HM et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 2007;50(4):733-40.
34. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.